Preclinical

Bespoke suite of in vivo services to rapidly advance therapeutic development

Our Preclinical Services

Our bespoke in vivo services enable the advancement of therapeutics from comprehensive in-life assessment through to histopathological analysis, covering a wide range of disease areas. Highly agile and tailored to specific scientific needs, the team approaches each programme from first principles to ensure that potential therapeutics have the best path to the clinic.

What We Do

EVALUATE AND DEVELOP RELEVANT ANIMAL MODELS

Generate or source and characterise transgenic animals
Specialise in breeding and maintenance of complex genetic crosses and special care rodent strains
Evaluate the mechanism bringing about the disease state, and their predicted translatability
Anticipate interactions of potential therapeutic with model.
Review previous data and experience to inform approach
Engage with internal and external network of experts to guide selection
Source relevant existing or develop bespoke model to answer the scientific question
Conduct pilot studies to determine performance of model in our hands

TEST AGENT PROFILING AND EFFICACY

Fully characterise potential therapeutics in vivo (PK/PD, tolerability, biomarker collection and analysis)
Emphasis on conducting efficacy studies that maximise translatability and reproducibility
Enhance the relevant therapeutic range for the desired endpoints
Flexible, agile approach to study design, with in-life real-time decision-making
Experienced with a wide range of therapeutic modalities, including small molecules, biologics, AAVs and cell-based therapies
Access to state-of-the-art in vivo equipment across our network for a variety of in vivo readouts
Fully integrated in-life and ex vivo analysis within our biology and bioanalysis teams
Full investigation of unexpected adverse effects of therapeutics, including histological analysis of tissues

Previous Programmes

Our highly talented team of scientists have experience spanning all elements of the drug discovery pathway in a wide range of disease areas and specialisms:

Inflammation (sepsis, lupus, osteoarthritis, IBD, renal disease, allergic asthma, rheumatoid arthritis, graft versus host disease)
Bleeding disorders (Haemophilia A and B, Glanzmann’s thrombasthenia)
Cardiovascular and metabolic (MASLD/MASH, pulmonary arterial hypertension, obesity, type 2 diabetes)
Oncology (xenograft, orthotopic, metastatic)
Fibrosis (idiopathic pulmonary fibrosis)
Neurological (stroke, neurodegeneration)

Case Study: RxCelerate's approach to oncology drug discovery and development

Find out more about our extensive experience with oncology models and how we approach tumour analysis. We provide a range of models to align with stage of discovery and development, from proof-of-concept through to multiple indication efficacy. ensuring our models represent translatable tools as close to the human disease as possible.

Read our case study

Poster: Histological characterisation of a bleomycin induced model of pulmonary fibrosis in mice

We have been exploring the analytical approaches used in the bleomycin model of pulmonary fibrosis and discovering what immunohistochemistry (IHC) and digital image analysis can reveal beyond the common endpoints in bleomycin-challenged lung tissue.

Read our poster

A leading drug discovery and development platform based in Cambridge (UK) delivering integrated programmes to our clients.

Get in touch

Call Us 01223 839557
Email Us [email protected]

Visit Us

The Dorothy Hodgkin Building,
Babraham Research Campus,
Babraham, Cambridge CB22 3FH